1.
Wiener Klinische Wochenschrift
; 133(SUPPL 6):225-225, 2021.
Article
in English
| Web of Science | ID: covidwho-1548127
2.
Wiener Klinische Wochenschrift
; 133(SUPPL 6):223-224, 2021.
Article
in English
| Web of Science | ID: covidwho-1548126
3.
Wiener Klinische Wochenschrift
; 133(SUPPL 3):S75-S76, 2021.
Article
in English
| Web of Science | ID: covidwho-1261655
4.
Clin Microbiol Infect
; 26(11): 1493-1494, 2020 Nov.
Article
in English
| MEDLINE | ID: covidwho-987339
Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Multiple Organ Failure/etiology , Sepsis/diagnostic imaging , Tuberculosis/diagnosis , Antibodies, Monoclonal, Humanized/therapeutic use , Drug Therapy, Combination , Ethambutol/therapeutic use , Female , Humans , Isoniazid/therapeutic use , Middle Aged , Multiple Organ Failure/drug therapy , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/isolation & purification , Pyrazinamide/therapeutic use , Rifampin/therapeutic use , Sepsis/chemically induced , Sepsis/drug therapy , Treatment Outcome , Tuberculosis/chemically induced , Tuberculosis/drug therapy
5.
Wiener Klinische Wochenschrift
; 132(SUPPL 5):S182-S183, 2020.
Article
in English
| Web of Science | ID: covidwho-938073